Glucose 10% Labesfal

Glucose 10% Labesfal is an intravenous solution containing 10 % w/v glucose as the sole active ingredient. It is supplied as a sterile, aqueous carbohydrate solution intended for parenteral administration. The product is classified as a carbohydrate solution and is marketed in the European Union for prescription use. It provides an exogenous source of glucose for patients requiring fluid, electrolyte, or nutritional support in clinical practice.

Glucose 10% Labesfal is used when rapid elevation of plasma glucose is required or when carbohydrate calories are needed as part of parenteral therapy. Indications include: - Treatment of hypoglycemia in adults and children. - Component of total parenteral nutrition regimens. - Fluid and electrolyte replacement in patients unable to tolerate oral intake. - Support during perioperative periods when fasting is required. - Management of metabolic disorders that limit endogenous glucose production.

Adverse reactions to Glucose 10% Labesfal are generally related to the infusion itself or to rapid changes in blood glucose.

Common: - Local irritation at the infusion site. - Mild hyperglycemia. - Nausea or vomiting. - Headache.

Serious: - Severe hyperglycemia with osmotic diuresis. - Electrolyte imbalance (e.g., hyponatremia). - Allergic reaction such as urticaria or anaphylaxis. - Volume overload leading to pulmonary edema.

Before initiating therapy with Glucose 10% Labesfal, clinicians should evaluate patient-specific factors and monitor relevant parameters. - Assess baseline blood glucose and adjust infusion rate accordingly. - Monitor electrolytes, especially sodium and potassium, during prolonged administration. - Use caution in patients with renal or cardiac insufficiency due to risk of fluid overload. - Avoid rapid infusion in neonates and infants. - Consider compatibility with other IV medications; do not mix with calcium‑containing solutions. - Discontinue or adjust dose if signs of hyperglycemia develop.

Glucose 10% Labesfal may affect the pharmacokinetics or pharmacodynamics of certain co‑administered drugs.

Avoid: - Concurrent use with insulin bolus doses without appropriate glucose monitoring. - Simultaneous infusion of high‑dose potassium chloride, which may precipitate in the solution.

Use with caution: - Diuretics that alter electrolyte balance, requiring closer monitoring. - Beta‑blockers that can mask hypoglycemia symptoms. - Corticosteroids that increase glucose production, potentially leading to hyperglycemia. - Oral hypoglycemic agents, as intravenous glucose can counteract their effect.